Role of fecal calprotectin in gastrointestinal disorders

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 12, 2013, Pages 1569-1582

  Montalto, Massimo ^a   Gallo, A ^a   Santoro, L ^a   D'Onofrio, F ^a   Landolfi, R ^a   Gasbarrini, A ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Fecal calprotectin; IBD; Intestinal inflammation

Indexed keywords

CALGRANULIN; NONSTEROID ANTIINFLAMMATORY AGENT;

DIAGNOSTIC ACCURACY; DISEASE MARKER; ENDOSCOPY; ENTERITIS; ENTEROPATHY; GASTROINTESTINAL DISEASE; HUMAN; NSAID ENTEROPATHY; PROGNOSIS; RELAPSE; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FECES; GASTROINTESTINAL DISEASES; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX;

EID: 84884332483     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. GISBERT JP, MCNICHOLL AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009; 41: 56-66.
2. FAGERHOL MK. Calprotectin, a faecal marker of organic gastrointestinal abnormality. Lancet 2000; 356: 1783-1784.
3. COSTA F, MUMOLO MG, BELLINI M, ROMANO MR, CECCARELLI L, ARPE P, STERPI C, MARCHI S, MALTINTI G. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003; 35: 642-647.
4. JOHNE B, FAGERHOL MK, LYBERG T, PRYDZ H, BRANDTZAEG P, NAESS-ANDRESEN CF, DALE I. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 1997; 50: 113-123.
5. BJERKE K, HALSTENSEN TS, JAHNSEN F, PULFORD K, BRANDTZAEG P. Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut 1993; 34: 1357-1363.
6. VERMEIRE S, VAN ASSCHE G, RUTGEERTS P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006; 55: 426-431.
7. TIBBLE JA, SIGTHORSSON G, BRIDGER S, FAGERHOL MK, BJARNASON I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22.
8. RØSETH AG, FAGERHOL MK, AADLAND E, SCHJØNSBY H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992; 27: 793-798.
9. ANGRIMAN I, SCARPA M, D'INCÀ R, BASSO D, RUFFOLO C, POLESE L, STURNIOLO GC, D'AMICO DF, PLEBANI M. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta 2007; 381: 63-68.
10. KONIKOFF MR, DENSON LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 524-534.
11. TIBBLE J, TEAHON K, THJODLEIFSSON B, ROSETH A, SIGTHORSSON G, BRIDGER S, FOSTER R, SHERWOOD R, FAGERHOL M, BJARNASON I. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000; 47: 506-513.
12. DAMMS A, BISCHOFF SC. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. Int J Colorectal Dis 2008; 23: 985-992.
13. D'INCÀ R, DAL PONT E, DI LEO V, FERRONATO A, FRIES W, VETTORATO MG, MARTINES D, STURNIOLO GC. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007; 22: 429-437.
14. JOHNSON MW, MAESTRANZI S, DUFFY AM, DEWAR DH, FORBES A, BJARNASON I, SHERWOOD RA, CICLITIRA P, NICHOLLS JR. Faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis. Eur J Gastroenterol Hepatol 2008; 20: 174-179.
15. COSTA F, MUMOLO MG, CECCARELLI L, BELLINI M, ROMANO MR, STERPI C, RICCHIUTI A, MARCHI S, BOTTAI M. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005; 54: 364-368.
16. SUTHERLAND AD, GEARRY RB, FRIZELLE FA. Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum 2008; 51: 1283-1291.
17. POULLIS A, FOSTER R, MENDALL MA, FAGERHOL MK. Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol 2003; 18: 756-762.
18. ROSETH AG, SCHMIDT PN, FAGERHOL MK. Correlation between faecal excretion of Indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 50-54.
19. TIBBLE JA, SIGTHORSSON G, FOSTER R, FORGACS I, BJARNASON I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from non-organic intestinal disease. Gastroenterology 2002; 123: 450-460.
20. GARCÍA SÁNCHEZ MDEL V, GONZÁLEZ R, IGLESIAS FLORES E, GÓMEZ CAMACHO F, CASAIS JUANENA L, CEREZO RUIZ A, MONTERO PÉREZ-BARQUERO M, MUNTANÉ J, DE DIOS VEGA JF. Diagnostic value of fecal calprotectin in predicting an abnormal colonoscopy. Med Clin (Barc) 2006; 127: 41-46.
21. SCHOEPFER AM, TRUMMLER M, SEEHOLZER P, SEIBOLDSCHMID B, SEIBOLD F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008; 14: 32-39.
22. LIMBURG PJ, AHLQUIST DA, SANDBORN WJ, MAHONEY DW, DEVENS ME, HARRINGTON JJ, ZINSMEISTER AR. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol 2000; 95: 2831-2837.
23. VON ROON AC, KARAMOUNTZOS L, PURKAYASTHA S, REESE GE, DARZI AW, TEARE JP, PARASKEVA P, TEKKIS PP. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007; 102: 803-813.
24. VAN RHEENEN PF, VAN DE VIJVER E, FIDLER V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. Br Med J 2010; 15: 341: c3369.
25. REESE GE, CONSTANTINIDES VA, SIMILLIS C, DARZI AW, ORCHARD TR, FAZIO VW, TEKKIS PP. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol 2006; 101: 2410-2422.
26. DIAMANTI A, PANETTA F, BASSO MS, FORGIONE A, COLISTRO F, BRACCI F, PAPADATOU B, FRANCALANCI P, TORRONI F, KNAFELZ D, FINA F, CASTRO M. Diagnostic work-up of inflammatory bowel disease in chil-dren: the role of calprotectin assay. Inflamm Bowel Dis 2010; 16: 1926-1930.
27. MINDEMARK M, LARSSON A. Ruling out IBD: Estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin. Clin Biochem 2012; 45: 552-555.
28. FOELL D, WITTKOWSKI H, ROTH J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut 2009; 58: 859-868.
29. SIDLER MA, LEACH ST, DAY AS. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis 2008; 14: 359-366.
30. SCHOEPFER AM, BEGLINGER C, STRAUMANN A, TRUMMLER M, RENZULLI P, SEIBOLD F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009; 15: 1851-1858.
31. BUNN SK, BISSET WM, MAIN MJ, GOLDEN BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 32: 171-177.
32. SIPPONEN T, KÄRKKÄINEN P, SAVILAHTI E, KOLHO KL, NUUTINEN H, TURUNEN U, FÄRKKILÄ M. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008; 28: 1221-1229.
33. SIPPONEN T, SAVILAHTI E, KOLHO KL, NUUTINEN H, TURUNEN U, FÄRKKILÄ M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008; 14: 40-46.
34. SCHOEPFER AM, BEGLINGER C, STRAUMANN A, TRUMMLER M, VAVRICKA SR, BRUEGGER LE, SEIBOLD F. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105: 162-169.
35. CANANI RB, TERRIN G, RAPACCIUOLO L, MIELE E, SIANI MC, PUZONE C, COSENZA L, STAIANO A, TRONCONE R. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 2008; 40: 547-553.
36. FAGERBERG UL, LÖÖF L, MYRDAL U, HANSSON LO, FINKEL Y. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 2005; 40: 450-455.
37. FAGERBERG UL, LÖÖF L, LINDHOLM J, HANSSON LO, FINKEL Y. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 45: 414-420.
38. JENSEN MD, KJELDSEN J, NATHAN T. Fecal calprotectin is equally sensitive in Crohn's disease affecting the small bowel and colon. Scand J Gastroenterol 2011; 46: 694-700.
39. BREMNER A, ROKED S, ROBINSON R, PHILLIPS I, BEATTIE M. Faecal calprotectin in children with chronic gastrointestinal symptoms. Acta Paediatr 2005; 94: 1855-1858.
40. KOLHO KL, RAIVIO T, LINDAHL H, SAVILAHTI E. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol 2006; 41: 720-725.
41. SIPPONEN T, SAVILAHTI E, KÄRKKÄINEN P, KOLHO KL, NUUTINEN H, TURUNEN U, FÄRKKILÄ M. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008; 14: 1392-1398.
42. SIPPONEN T, BJÖRKESTEN CG, FÄRKKILÄ M, NUUTINEN H, SAVILAHTI E, KOLHO KL. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol 2010; 45: 325-331.
43. HO GT, LEE HM, BRYDON G, TING T, HARE N, DRUMMOND H, SHAND AG, BARTOLO DC, WILSON RG, DUNLOP MG, ARNOTT ID, SATSANGI J. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol 2009; 104: 673-678.
44. TURNER D, LEACH ST, MACK D, UUSOUE K, MCLERNON R, HYAMS J, LELEIKO N, WALTERS TD, CRANDALL W, MARKOWITZ J, OTLEY AR, GRIFFITHS AM, DAY AS. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut 2010; 59: 1207-1212.
45. HÄMÄLÄINEN A, SIPPONEN T, KOLHO KL. Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels. World J Gastroenterol 2011; 17: 5166-5171.
46. D'INCÀ R, DAL PONT E, DI LEO V, BENAZZATO L, MARTINATO M, LAMBOGLIA F, OLIVA L, STURNIOLO GC. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 2008; 103: 2007-2014.
47. GARCÍA-SÁNCHEZ V, IGLESIAS-FLORES E, GONZÁLEZ R, GISBERT JP, GALLARDO-VALVERDE JM, GONZÁLEZ-GALILEA A, NARANJO-RODRÍGUEZ A, DE DIOS-VEGA JF, MUNTANÉ J, GÓMEZ-CAMACHO F. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J Crohns Colitis 2010; 4: 144-152.
48. SIPPONEN T, KOLHO KL. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol 2010; 45: 872-877.
49. LAMB CA, MOHIUDDIN MK, GICQUEL J, NEELY D, BERGIN FG, HANSON JM, MANSFIELD JC. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br J Surg 2009; 96: 663-674.
50. SCARPA M, D'INCÀ R, BASSO D, RUFFOLO C, POLESE L, BERTIN E, LUISE A, FREGO M, PLEBANI M, STURNIOLO GC, D'AMICO DF, ANGRIMAN I. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease. Dis Colon Rectum 2007; 50: 861-869.
51. THOMAS P, RIHANI H, RØSETH A, SIGTHORSSON G, PRICE A, NICHOLLS RJ, BJARNASON I. Assessment of ileal pouch inflammation by single-stool calprotectin assay. Dis Colon Rectum 2000; 43: 214-220.
52. SÖDERHOLM JD, OLAISON G, LINDBERG E, HANNESTAD U, VINDELS A, TYSK C, JÄRNEROT G, SJÖDAHL R. Different intestinal permeability patterns in relatives and spouses of patients with Crohn's disease: An inherited defect in mucosal defence? Gut 1999; 44: 96-100.
53. MUNKHOLM P, LANGHOLZ E, HOLLANDER D, THORNBERG K, ORHOLM M, KATZ KD, BINDER V. Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first-degree relatives. Gut 1994; 35: 68-72.
54. THJODLEIFSSON B, SIGTHORSSON G, CARIGLIA N, REYNISDOTTIR I, GUDBJARTSSON DF, KRISTJANSSON K, MEDDINGS JB, GUDNASON V, WANDALL JH, ANDERSEN LP, SHERWOOD R, KJELD M, ODDSSON E, GUDJONSSON H, BJARNASON I. Subclinical intestinal inflammation: an inherited abnormality in Crohn's disease relatives? Gastroenterology 2003; 124: 1728-1737.
55. MONTALTO M, CURIGLIANO V, SANTORO L, ARMUZZI A, CAMMAROTA G, COVINO M, MENTELLA MC, ANCARANI F, MANNA R, GASBARRINI A, GASBARRINI G. Fecal calprotectin in first-degree relatives of patients with ulcerative colitis. Am J Gastroenterol 2007; 102: 132-136.
56. PHAM M, LEACH ST, LEMBERG DA, DAY AS. Subclinical intestinal inflammation in siblings of children with Crohn's disease. Dig Dis Sci 2010; 55: 3502-3507.
57. GRAHAM DY, OPEKUN AR, WILLINGHAM FF, QURESHI WA. Visible small intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005; 3: 55-59.
58. HIGUCHI K, UMEGAKI E, WATANABE T, YODA Y, MORITA E, MURANO M, TOKIOKA S, ARAKAWA T. Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol 2009; 44: 879-888.
59. MAIDEN L, THJODLEIFSSON B, THEODORS A, GONZALEZ J, BJARNASON I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005; 128: 1172-1178.
60. TIBBLE JA, SIGTHORSSON G, FOSTER R, SCOTT D, FAGERHOL MK, ROSETH A, BJARNASON I. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999; 45: 362-366.
61. MELING TR, AABAKKEN L, RØSETH A, OSNES M. Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 1996; 31: 339-344.
62. HAWKEY CJ, ELL C, SIMON B, ALBERT J, KEUCHEL M, MCALINDON M, FORTUN P, SCHUMANN S, BOLTEN W, SHONDE A, HUGOT JL, YU V, ARULMANI U, KRAMMER G, REBULI R, TOTH E. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clin Gastroenterol Hepatol 2008; 6: 536-544.
63. MONTALTO M, CURIGLIANO V, SANTORO L, LOMBARDI M, COVINO M, CAMMAROTA G, DALVAI S, D'ONOFRIO F, GASBARRINI A, GASBARRINI G. Prophylactic aspirin therapy does not increase faecal calprotectin concentrations. Eur J Gastroenterol Hepatol 2006; 18: 965-967.
64. SMECUOL E, PINTO SANCHEZ MI, SUAREZ A, ARGONZ JE, SUGAI E, VAZQUEZ H, LITWIN N, PIAZUELO E, MEDDINGS JB, BAI JC, LANAS A. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol 2009; 7: 524-529.
65. PEZZILLI R, BARASSI A, MORSELLI LABATE AM, FINAZZI S, FANTINI L, GIZZI G, LOTZNIKER M, VILLANI V, MELZI D'ERIL G, CORINALDESI R. Fecal calprotectin levels in patients with colonic polyposis. Dig Dis Sci 2008; 53: 47-51.
66. LIMBURG PJ, DEVENS ME, HARRINGTON JJ, DIEHL NN, MAHONEY DW, AHLQUIST DA. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia. Am J Gastroenterol 2003; 98: 2299-2305.
67. SCHOLEFIELD JH, MOSS S, SUFI F, MANGHAM CM, HARDCASTLE JD. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomized controlled trial. Gut 2002; 50: 840-844.
68. TIBBLE J, SIGTHORSSON G, FOSTER R, SHERWOOD R, FAGERHOL M, BJARNASON I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001; 49: 402-408.
69. KRONBORG O, UGSTAD M, FUGLERUD P, JOHNE B, HARDCASTLE J, SCHOLEFIELD JH, VELLACOTT K, MOSHAKIS V, REYNOLDS JR. Fecal calprotectin levels in a highrisk population for colorectal neoplasia. Gut 2000; 46: 795-800.
70. KRISTINSSON J, ARMBRUSTER CH, UGSTAD M, KRIWANEK S, NYGAARD K, TØN H, FUGLERUD P. Fecal excretion of calprotectin in colorectal cancer relationship to tumor characteristics. Scand J Gastroenterol 2001; 36: 202-207.
71. SUMMERTON CB, LONGLANDS MG, WIENER K, SHREEVE DR. Faecal calprotectin: A marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002; 14: 841-845.
72. JOHNE B, KRONBORG O, TON HI, KRISTINSSON J, FUGLERUD P. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method. Scand J Gastroenterol 2001; 36: 291-296.
73. GILBERT JA, AHLQUIST DA, MAHONEY DW, ZINSMEISTER AR, RUBIN J, ELLEFSON RD. Fecal marker variability in colorectal cancer: calprotectin versus hemoglobin. Scand J Gastroenterol 1996; 31: 1001-1005.
74. HOFF G, GROTMOL T, THIIS-EVENSEN E, BRETTHAUER M, GONDAL G, VATN MH. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut 2004; 53: 1329-1333.
75. TURSI A, BRANDIMARTE G, ELISEI W, GIORGETTI GM, INCHINGOLO CD, AIELLO F. Faecal calprotectin in colonic diverticular disease: a case-control study. Int J Colorectal Dis 2009; 24: 49-55.
76. HALLGREN R, COLOMBEL JF, DAHL R, FREDENS K, KRUSE A, JACOBSEN NO, VENGE P, RAMBAUD JC. Neutrophil and eosinophil involvement of small bowel in patients with celiac disease and Crohn's disease: studies on the secretion rate and immunohistochemical localization of granulocyte granule constituens. Am J Med 1989; 86: 56-64.
77. MONTALTO M, SANTORO L, CURIGLIANO V, D'ONOFRIO F, CAMMAROTA G, PANUNZI S, RICCI R, GALLO A, GRIECO A, GASBARRINI A, GASBARRINI G. Faecal calprotectin concentrations in untreated coeliac patients. Scand J Gastroenterol 2007; 42: 957-961.
78. ERTEKIN V, SELIMOGLU MA, TURGUT A, BAKAN N. Fecal calprotectin concentration in celiac disease. J Clin Gastroenterol 2010; 44: 544-546.
79. SUMMERTON CB, LONGLANDS MG, WIENER K, SHREEVE DR. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002; 14: 841-845.
80. MONTALTO M, GALLO A, IANIRO G, SANTORO L, D'ONOFRIO F, RICCI R, CAMMAROTA G, COVINO M, VASTOLA M, GASBARRINI A, GASBARRINI G. Can chronic gastritis cause an increase in fecal calprotectin concentrations? World J Gastroenterol 2010; 16: 3406-3410.
81. TOSKES PP, GIANNELLA RA, JERVIS HR, ROUT WR, TAKEUCHI A. Small intestinal mucosal injury in the experimental blind loop syndrome. Light- and electon-microscopic and histochemical studies. Gastroenterology 1975; 68: 1193-1203.
82. MONTALTO M, SANTORO L, DALVAI S, CURIGLIANO V, D'ONOFRIO F, SCARPELLINI E, CAMMAROTA G, PANUNZI S, GALLO A, GASBARRINI A, GASBARRINI G. Fecal calprotectin concentrations in patients with small intestinal bacterial overgrowth. Dig Dis 2008; 26: 183-186.
83. BODE C, BODE JC. Effect of alcohol consumption on the gut. Best Pract Res Clin Gastroenterol 2003; 17: 575-592.
84. FOSTER R, BJARNASON IB, ROSETH AG, FAGERHOL MK, PETERA TJ. Alcohol misuse causes a reversible inflammatory enteropathy with increased intestinal permeability. Alcohol Alcohol 1995; 30: C5.2.
85. MONTALTO M, GALLO A, FERRULLI A, VISCA D, CAMPOBASSO E, CARDONE S, D'ONOFRIO F, SANTORO L, COVINO M, MIRIJELLO A, LEGGIO L, GASBARRINI G, ADDOLORATO G. Fecal calprotectin concentrations in alcoholic patients: a longitudinal study. Eur J Gastroenterol Hepatol 2011; 23: 76-80.